Yahoo
OTC Markets OTCID USD

Enzolytics, Inc. (ENZC)

0.0004 0.0000 (0.00%)
At close: October 30 at 4:00:00 PM EDT
Chart Range Bar
Loading chart for ENZC
  • Previous Close 0.0004
  • Open 0.0004
  • Bid 0.0003 x 3232358000
  • Ask 0.0004 x 2000000
  • Day's Range 0.0004 - 0.0004
  • 52 Week Range 0.0002 - 0.0013
  • Volume 12,662
  • Avg. Volume 3,578,490
  • Market Cap (intraday) 1.932M
  • Beta (5Y Monthly) 0.74
  • PE Ratio (TTM) --
  • EPS (TTM) -0.3400
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est --

Enzolytics, Inc. a drug development company, focuses on the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. It's patented anti-HIV therapeutics and a proprietary methodology for producing human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. The company has clinically tested anti-HIV therapeutics. In addition, the company's proprietary cell line produces human monoclonal antibodies that target and neutralize the HIV virus. Enzolytics, Inc. is based in Allen, Texas.

enzolytics.com

--

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ENZC
33.33%
S&P 500 (^GSPC)
10.73%

1-Year Return

ENZC
14.29%
S&P 500 (^GSPC)
11.11%

3-Year Return

ENZC
98.66%
S&P 500 (^GSPC)
81.91%

5-Year Return

ENZC
99.68%
S&P 500 (^GSPC)
64.59%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -704.70%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    46.59k

  • Net Income Avi to Common (ttm)

    -1.03M

  • Diluted EPS (ttm)

    -0.3400

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    5.76k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    151.19k

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: